Sensus Healthcare Inc
NASDAQ:SRTS

Watchlist Manager
Sensus Healthcare Inc Logo
Sensus Healthcare Inc
NASDAQ:SRTS
Watchlist
Price: 8.89 USD -0.45% Market Closed
Market Cap: 145.7m USD
Have any thoughts about
Sensus Healthcare Inc?
Write Note

Sensus Healthcare Inc
Long-Term Investments

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Sensus Healthcare Inc
Long-Term Investments Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Investments CAGR 3Y CAGR 5Y CAGR 10Y
Sensus Healthcare Inc
NASDAQ:SRTS
Long-Term Investments
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Long-Term Investments
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Boston Scientific Corp
NYSE:BSX
Long-Term Investments
$532m
CAGR 3-Years
7%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Stryker Corp
NYSE:SYK
Long-Term Investments
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbott Laboratories
NYSE:ABT
Long-Term Investments
$877m
CAGR 3-Years
3%
CAGR 5-Years
0%
CAGR 10-Years
15%
Intuitive Surgical Inc
NASDAQ:ISRG
Long-Term Investments
$4.1B
CAGR 3-Years
0%
CAGR 5-Years
10%
CAGR 10-Years
13%
No Stocks Found

Sensus Healthcare Inc
Glance View

Market Cap
145.7m USD
Industry
Health Care

Sensus Healthcare, Inc. operates as a medical device company, which provides treatments for both oncological and non-oncological skin conditions. The company is headquartered in Boca Raton, Florida and currently employs 37 full-time employees. The company went IPO on 2016-06-03. The firm is focused on providing non-invasive treatments for both oncological and non-oncological skin conditions. The firm uses a low-energy X-ray technology known as superficial radiation therapy (SRT). The firm incorporated SRT into its portfolio of treatment devices: the SRT-100, SRT-100 Plus and SRT-100 Vision. SRT-100, is a photon x-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers and other skin conditions such as keloids. The SRT-100 Vision provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. Its SRT-100 Plus offers remote diagnostics solutions, including operation tracking.

SRTS Intrinsic Value
10.46 USD
Undervaluation 15%
Intrinsic Value
Price

See Also

Back to Top